BR0317064A - Administração de células dentrìticas parcialmente amadurecidas in vitro para o tratamento de tumores - Google Patents

Administração de células dentrìticas parcialmente amadurecidas in vitro para o tratamento de tumores

Info

Publication number
BR0317064A
BR0317064A BR0317064-0A BR0317064A BR0317064A BR 0317064 A BR0317064 A BR 0317064A BR 0317064 A BR0317064 A BR 0317064A BR 0317064 A BR0317064 A BR 0317064A
Authority
BR
Brazil
Prior art keywords
administration
dendritic cells
cells
treatment
partially
Prior art date
Application number
BR0317064-0A
Other languages
English (en)
Other versions
BRPI0317064B1 (pt
BRPI0317064B8 (pt
Inventor
Marnix L Bosch
Original Assignee
Northwest Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics Inc filed Critical Northwest Biotherapeutics Inc
Publication of BR0317064A publication Critical patent/BR0317064A/pt
Publication of BRPI0317064B1 publication Critical patent/BRPI0317064B1/pt
Publication of BRPI0317064B8 publication Critical patent/BRPI0317064B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"ADMINISTRAçãO DE CéLULAS DENDRìTICAS PARCIALMENTE AMADURECIDAS IN VITRO PARA O TRATAMENTO DE TUMORES". A presente invenção refere-se a populações de células compreendendo células dendríticas parcialmente amadurecidas que podem ser usadas para a administração a indivíduos tendo um tumor. As células dendríticas parcialmente amadurecidas, que estiveram em contato com um agente de amadurecimento de células dendríticas durante cerca de 1 a cerca de 10 horas, ou mais, absorvem e processam antígenos de tumor eficazmente na área do sítio do tumor, completam o amadurecimento e podem, subseq³entemente, migrar para os linfonodos de um indivíduo tratado. Uma vez no linfonodo, as células dendríticas apresentando antígenos agora completamente amadurecidas secretam as citocinas apropriadas (por exemplo TNF <244> e IL12) e contatam as células T induzindo uma resposta imune antitumor substancial.
BRPI0317064A 2002-12-06 2003-12-05 composições compreendendo células dendríticas parcialmente amadurecidas in vitro BRPI0317064B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43126702P 2002-12-06 2002-12-06
US60/431,267 2002-12-06
PCT/US2003/038672 WO2004053072A2 (en) 2002-12-06 2003-12-05 Administration of dendritic cells partially matured in vitro for the treatment of tumors

Publications (3)

Publication Number Publication Date
BR0317064A true BR0317064A (pt) 2005-10-25
BRPI0317064B1 BRPI0317064B1 (pt) 2020-11-03
BRPI0317064B8 BRPI0317064B8 (pt) 2021-05-25

Family

ID=32507696

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0317064A BRPI0317064B8 (pt) 2002-12-06 2003-12-05 composições compreendendo células dendríticas parcialmente amadurecidas in vitro

Country Status (19)

Country Link
US (2) US20060057120A1 (pt)
EP (2) EP1567155B1 (pt)
JP (2) JP4859169B2 (pt)
KR (1) KR101144196B1 (pt)
CN (2) CN102600461B (pt)
AT (1) ATE486125T1 (pt)
AU (2) AU2003293411B2 (pt)
BR (1) BRPI0317064B8 (pt)
CA (1) CA2509058A1 (pt)
DE (1) DE60334725D1 (pt)
DK (1) DK1567155T3 (pt)
ES (1) ES2354944T3 (pt)
HK (1) HK1082180A1 (pt)
IL (1) IL169002A (pt)
MX (1) MXPA05006042A (pt)
PL (1) PL377209A1 (pt)
PT (1) PT1567155E (pt)
RU (1) RU2348418C2 (pt)
WO (1) WO2004053072A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102600461B (zh) * 2002-12-06 2017-07-14 西北生物治疗药物公司 给予体外部分成熟的树突细胞治疗肿瘤
EP1720567A2 (en) * 2004-02-10 2006-11-15 Innate Pharma Composition and method for the treatment of carcinoma
US20060216269A1 (en) * 2004-09-17 2006-09-28 Kenichiro Hasumi Dendritic cell tumor injection (DCTI) therapy
US8076132B2 (en) 2004-09-17 2011-12-13 Hasumi International Research Foundation Dendritic cell tumor injection (DCTI) therapy
WO2006095330A2 (en) * 2005-03-10 2006-09-14 Yeda Research And Development Co. Ltd. Methods and immunogenic cell preparations for treating antigen-associated diseases
WO2007001200A1 (fr) * 2005-06-23 2007-01-04 Obschestvo S Ogranichennoi Otvetsvennostyu 'rusgen' Cellules dendritiques matures chargees d'un polylysat de tumeurs, et vaccin antitumoral a base desdites cellules
AR060424A1 (es) * 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
WO2008133595A1 (en) * 2007-04-26 2008-11-06 Newbiomed Pika Pte Ltd Compositions and methods for stimulating an immune response in-vivo and in-vitro
WO2008151389A1 (en) * 2007-06-15 2008-12-18 Macfarlane Burnet Institute For Medical Research And Public Health Limited Chemically modified macromolecules
EP2072617A1 (en) * 2007-12-12 2009-06-24 Trimed Biotech GmbH Method for producing dendritic cells
EP2268794B1 (en) * 2008-03-27 2017-09-13 Asterias Biotherapeutics, Inc. Differentiation of primate pluripotent stem cells to hematopoietic lineage cells
PL2451943T3 (pl) * 2009-07-09 2017-04-28 Tigenix, S.A.U. Sposoby i kompozycje do zastosowania w terapiach komórkowych
RU2565542C2 (ru) * 2010-02-10 2015-10-20 Иммуникум Аб Улучшенная композиция для ингибирования пролиферации опухолевых клеток
RU2530523C2 (ru) * 2012-03-29 2014-10-10 Олег Борисович Егоров Способ противоопухолевой иммунотерапии
WO2014004809A2 (en) * 2012-06-27 2014-01-03 Hasumi International Research Foundation Therapy and method for intratumorally introducing cytotoxic t lymphocyte and/or nkt cell with anti-tnf and/or anti-il-10
GB201300049D0 (en) * 2013-01-03 2013-02-20 Transimmune Ag Method for obtaining immuno-stimulatory dendritic cells
AU2014346852A1 (en) 2013-11-05 2016-06-16 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
GB201413665D0 (en) * 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
CN114774356A (zh) * 2015-06-30 2022-07-22 西北生物治疗药物公司 诱发改善的或增加的抗肿瘤免疫应答的经最佳活化的树突细胞
CN108291204A (zh) 2015-09-15 2018-07-17 西北生物治疗药物公司 涉及用于患有晚期癌症的受试者的经活化树突状细胞组合物和免疫治疗处理的方法
KR101749165B1 (ko) * 2016-06-07 2017-06-23 충남대학교산학협력단 Rv2299c 또는 Rv2299c와 ESAT-6 융합한 단백질을 포함하는 수지상 세포의 성숙화 촉진용 조성물
WO2018160666A1 (en) * 2017-02-28 2018-09-07 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Short-term activated dc1s and methods for their production and use
GB201711379D0 (en) * 2017-07-14 2017-08-30 Univ Cape Town Maturation of dendritic cells
CN109957548B (zh) * 2017-12-26 2022-03-18 上海尚泰生物技术有限公司 一种基因修饰的树突状细胞疫苗

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0633929B1 (en) 1992-04-01 2004-03-03 The Rockefeller University METHOD FOR $i(IN VITRO) PROLIFERATION OF DENDRITIC CELL PRECURSORS AND THEIR USE TO PRODUCE IMMUNOGENS
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US6797488B1 (en) * 1997-12-08 2004-09-28 Beth Israel Deaconess Medical Center Methods of producing anti-angiogenic proteins
CN1330557A (zh) * 1998-09-15 2002-01-09 匹兹堡大学联邦系统高等教育 原位注射具有基因上增进细胞因子表达的抗原呈递细胞
WO2000020563A1 (fr) * 1998-10-02 2000-04-13 Mitsubishi Chemical Corporation Procede d'induction d'une immunite cellulaire et cellules possedant cette immunite
US6649158B1 (en) * 1998-10-15 2003-11-18 Canji, Inc. Methods and compositions to induce antitumor response
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
JP2002541195A (ja) * 1999-04-14 2002-12-03 アメリカ合衆国 移植片に対する免疫寛容を誘導するための、免疫毒素および樹状細胞の成熟を阻害する作用剤を含有する組成物
AU2403901A (en) * 1999-12-28 2001-07-09 Ichiro Azuma Maturation-promoting agent for immature dendritic cells
JP2002069001A (ja) * 2000-08-29 2002-03-08 Asahi Kasei Corp 樹状細胞を主成分とする細胞ワクチン
US20020094545A1 (en) 2000-11-30 2002-07-18 Harris Paul E. Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads
WO2003010292A2 (en) * 2001-07-25 2003-02-06 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors
WO2003022215A2 (en) * 2001-09-06 2003-03-20 Northwest Biotherapeutics, Inc. Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response
CN102600461B (zh) * 2002-12-06 2017-07-14 西北生物治疗药物公司 给予体外部分成熟的树突细胞治疗肿瘤
AU2004214896A1 (en) * 2003-02-27 2004-09-10 Northwest Biotherapeutics, Inc. Generation of dendritic cells from monocytic dendritic precursor cells with GM-CSF in the absence of additional cytokines

Also Published As

Publication number Publication date
DE60334725D1 (de) 2010-12-09
JP4859169B2 (ja) 2012-01-25
PL377209A1 (pl) 2006-01-23
CN1738619A (zh) 2006-02-22
JP2011246493A (ja) 2011-12-08
AU2011200352B2 (en) 2013-06-27
HK1082180A1 (en) 2006-06-02
BRPI0317064B1 (pt) 2020-11-03
RU2348418C2 (ru) 2009-03-10
CN102600461A (zh) 2012-07-25
PT1567155E (pt) 2011-01-28
MXPA05006042A (es) 2005-09-21
JP2006510667A (ja) 2006-03-30
JP5707284B2 (ja) 2015-04-30
AU2003293411B2 (en) 2010-10-28
EP2260861A1 (en) 2010-12-15
WO2004053072A3 (en) 2005-06-16
US20120251561A1 (en) 2012-10-04
KR20050084189A (ko) 2005-08-26
EP1567155A2 (en) 2005-08-31
IL169002A (en) 2015-01-29
CN102600461B (zh) 2017-07-14
ATE486125T1 (de) 2010-11-15
EP1567155B1 (en) 2010-10-27
ES2354944T3 (es) 2011-03-21
US20060057120A1 (en) 2006-03-16
CN1738619B (zh) 2012-04-18
EP1567155A4 (en) 2006-12-13
DK1567155T3 (da) 2011-02-14
BRPI0317064B8 (pt) 2021-05-25
AU2003293411A1 (en) 2004-06-30
CA2509058A1 (en) 2004-06-24
WO2004053072A2 (en) 2004-06-24
RU2005121256A (ru) 2006-02-10
AU2011200352A1 (en) 2011-02-17
KR101144196B1 (ko) 2012-05-21

Similar Documents

Publication Publication Date Title
BR0317064A (pt) Administração de células dentrìticas parcialmente amadurecidas in vitro para o tratamento de tumores
DE69030880D1 (de) Zusammensetzung zur Stimulierung des Immunsystems
CY1122817T1 (el) Νεα αντι-il 13 αντισωματα και χρησεις αυτων
NO821832L (no) Fremgangsmaate for fremstilling av allergenholdige kapsler
YU18899A (sh) L-nukleozidi purina, njihovi analogoni i primena
HUT63564A (en) Medical preparatives, method for producing them and their applications as analgetic and/or febrifuge in human and veterinary medicine
DE60239394D1 (de) Onkolytische virustherapie
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DK0502092T3 (da) Oralt præparat til behandling af inflammatoriske tarmsygdomme
DK0708772T3 (da) Imidazo[4,5,-c]pyridin-4-aminer
GEP20032976B (en) Artificial Peptides Having Surface Activity and Use Thereof in The Preparation of Artificial Surfactant
YU60900A (sh) Novi kristalni oblici antivirusnog benzimidazolskog jedinjenja
ATE174798T1 (de) Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
SE8400723L (sv) Farmaceutisk komposition
DE69108242D1 (de) Antikoagulanszubereitung.
ES2137172T3 (es) Vacunas antitumorales que comprenden celulas transfectadas con il-6.
YU40796A (sh) Preparati i postupci za tretiranje obolenja koja izazivaju t ćelije
MX9207150A (es) Metodo y composiciones para reducir la resistenciaa multiples farmacos.
PL424035A1 (pl) Optymalnie aktywowane komórki dendrytyczne, które indukują ulepszoną lub zwiększoną przeciwnowotworową odpowiedź odpornościową
PT1047422E (pt) Utilizacao de histamina para elevar os niveis de histamina no sangue
DK0538330T3 (da) Beta-Alethin-anvendelse til celledyrkning og terapi
PT1016414E (pt) Hormona de crescimento humano para estimular a hematopoiese e a reconstituicao imnologica apos transplante de celulas estaminais hematopoieticas em humanos
NO20022739D0 (no) Nye terapeutiske kombinasjoner av (S)-2-(benzylamino-metyl)- 2,3,8,9-tetrahydro-7H-1,4-dioksino[2,3-e]indol-8-on ognevroleptika for behandling eller forhindring av psykotiskelidelser
ATE376836T1 (de) Mucinpeptid mit immunstärkenden eigenschaften
DE69318166T2 (de) Mit morphogen angereicherte nahrungszusammenstellung

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: "PARA: INT. CL. A61K 31/44

Ipc: A61K 31/44 (2011.01), C12N 5/00 (2011.01), C12N 5/

Free format text: PARA: INT. CL. A61K 31/44; C12N 5/00; C12N 5/02; A61P 35/00

Ipc: A61K 31/44 (2011.01), C12N 5/00 (2011.01), C12N 5/

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/12/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2751 DE 26-09-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.